Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease

If you need an accessible version of this item, please submit a remediation request.
Date
2015-06-10
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
BioMed Central
Abstract

INTRODUCTION:

The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic effects and to examine the correlations among outcome measures.

METHODS:

The study was a multicenter, randomized, placebo-controlled trial of two dose regimens of semagacestat and a placebo administered for 18 months to individuals with mild to moderate AD. Changes in measures of central and peripheral drug activity were compared between the three treatment groups using one-way analysis of variance. The relationship between changes in each of the outcome measures and measures of drug exposure and peripheral pharmacodynamic effect were assessed using Spearman's correlation coefficient.

RESULTS:

Assignment to the active treatment arms was associated with reduction in plasma amyloid-β (Aβ) peptides, increase in ventricular volume, decrease in cerebrospinal fluid phosphorylated tau (p-tau) and several other laboratory measures and adverse event categories. Within the active arms, exposure to drug, as indicated by area under the concentration curve (AUC) of blood concentration, was associated with reduction in plasma Aβ peptides and a subset of laboratory changes and adverse event rates. Ventricular volume increase, right hippocampal volume loss and gastrointestinal symptoms were related to change in plasma Aβ peptide but not AUC, supporting a link to inhibition of γ-secretase cleavage of the amyloid precursor protein. Cognitive decline correlated with ventricular expansion and reduction in p-tau.

CONCLUSION:

These findings may inform future studies of drugs targeting secretases involved in Aβ generation.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Doody, R. S., Raman, R., Sperling, R. A., Seimers, E., Sethuraman, G., Mohs, R., … for the Alzheimer’s Disease Cooperative Study. (2015). Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease. Alzheimer’s Research & Therapy, 7(1), 36. http://doi.org/10.1186/s13195-015-0121-6
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Alzheimer’s Research & Therapy
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Full Text Available at
This item is under embargo {{howLong}}